PHASER – Pluridirectional High-energy Agile Scanning Electronic Radiotherapy

项目摘要/摘要 TibaRay，Inc.的使命是开发和临床翻译下一代放射治疗技术 用于治疗癌症，这是世界范围内唯一的主要死亡原因，而且在流行中不断增加。 放射治疗(RT)的一个重大进展是增加了其治疗潜力并减少了副作用 在3D中精致地雕刻辐射剂量的能力，以符合肿瘤并保留周围正常器官。 这种剂量塑造是通过从多个方向向肿瘤输送放射束来实现的，每个方向 具有优化的空间强度分布。然而，最快的治疗时间仍然是几分钟长的，有限的 由电子直线加速器中的束流强度和用于引导和塑造 治疗梁。 为了解决当前最先进的辐射传输系统的这些主要缺点，TibaRay提出了 一种全新的放射治疗系统设计--多向高能敏捷扫描电子放射治疗 (相位器)，基于产生强度调制治疗能量x射线的专利新技术 来自多个方向的梁，不使用机械系统来引导或塑造处理梁。这是 通过使用新型电子直线加速器阵列来实现，其中每个电子直线加速器都使用磁性电子束扫描 与扩展的韧致辐射目标和多通道准直器阵列系统配对的方案，称为 扫描笔阵列准直高速强度调制X射线源(Sphinx)。多个直线加速器 消除了在机架上移动单个直线加速器以实现不同波束方向的需要，并且Sphinx消除了 需要机械移动部件，例如多叶准直器(MLCs)，用于治疗光束整形。每一位 用于相控器的新型直线加速器比传统的医用激光器效率高得多，并将产生更多的光束 直线加速器。在全相位器设计中，估计处理时间可以减少到1秒以内， 有效地冻结了生理运动。新的加速器技术使用了简单得多的制造 相控器的技术和生产成本预计将与目前最先进的水平大致相同。 系统和维护/停机成本应该更低。 对移相器所需的子系统进行了初步的原理证明。TibaRay，输入 与斯坦福大学放射肿瘤学系和SLAC国家加速中心合作 实验室，建议设计(第一阶段)、建造和测试并优化双光束移相器原型(第一阶段 Ii)。在第三阶段，TibaRay将开发全相位器原型，这将直接导致商业化和 临床翻译。 我们的新技术将有助于满足全球对高质量、高成本效益的放射治疗的巨大需求。 治疗癌症。

PROJECT SUMMARY/ABSTRACT The mission of TibaRay, Inc. is to develop and clinically translate next-generation radiation therapy technologies for the treatment of cancer, the single leading cause of death worldwide and increasing epidemically. A major advance in radiation therapy (RT) that has increased its curative potential and decreased side effects is the ability to sculpt radiation doses exquisitely in 3D to conform to tumors and spare surrounding normal organs. This dose sculpting is achieved by delivering radiation beams to the tumor from multiple directions, each of which has an optimized spatial intensity distribution. However, the fastest treatment times are still minutes long, limited by both beam intensities in electron linacs and the mechanical systems that are used to direct and shape the treatment beams. To address these major shortcomings of current state-of-the-art radiation delivery systems, TibaRay is proposing a radical new design for RT systems, Pluridirectional High-energy Agile Scanning Electronic Radiotherapy (PHASER), based on patented, novel technologies to produce intensity-modulated therapeutic energy x-ray beams from multiple directions using no mechanical systems to direct or shape the treatment beams. This is achieved by using an array of novel electron linacs each of which uses a magnetic electron beam scanning scheme paired with an extended bremsstrahlung target and multi-channel collimator array system referred to as Scanning Pencil-array-collimated High Speed Intensity-modulated X-ray source (SPHINX). The multiple linacs obviate the need to move a single linac on a gantry to achieve different beam directions and SPHINX eliminates the need for mechanical moving parts, e.g., multi-leaf collimators (MLCs), for therapy beam shaping. Each of the novel linacs used in PHASER are far more efficient and will generate more beam than conventional medical linacs. In the full PHASER design, it is estimated that the treatment time can be reduced to less than one second, effectively freezing physiological motion. The novel accelerator technology uses much simpler manufacturing techniques and production costs for PHASER are projected to be about the same as current state-of-the-art systems and maintenance/downtime costs should be lower. Initial proof of principle for the subsystems needed for PHASER have been demonstrated. TibaRay, in partnership with the Stanford University Department of Radiation Oncology and the SLAC National Acceleratory Laboratory, proposes to design (Phase I), build and test, and optimize a two-beam PHASER prototype (Phase II). In Phase III, TibaRay will develop the full PHASER prototype which will lead directly to commercialization and clinical translation. Our novel technology will help fill a tremendous worldwide need for high-quality, cost-effective radiation therapy for cancer.